

FDA approves supplemental new drug application for Novartis therapy Gilenya® to include data showing reduction in T1 lesions in MS, a marker of disease activity

Aug 01, 2011

Source URL: <https://prod1.novartis.com/us-en/news/media-releases/fda-approves-supplemental-new-drug-application-novartis-therapy-gilenyatm-include-data-showing-reduction-t1-lesions-ms-marker-disease-activity-0>

List of links present in page

1. <https://prod1.novartis.com/us-en/us-en/news/media-releases/fda-approves-supplemental-new-drug-application-novartis-therapy-gilenyatm-include-data-showing-reduction-t1-lesions-ms-marker-disease-activity-0>